Stealth BioTherapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
Stealth BioTherapeutics (Nasdaq: MITO) will report its third quarter 2020 financial results on November 5, 2020, before markets open. Management will host a conference call at 8:30 am ET the same day to discuss the results and provide a business update. The event will be accessible via phone and a live webcast. Stealth BioTherapeutics focuses on developing therapies for mitochondrial dysfunction, with its lead candidate, elamipretide, targeting various mitochondrial diseases. Additionally, they are working on SBT-272 for rare neurodegenerative diseases like ALS.
- Lead candidate elamipretide aims to treat rare mitochondrial diseases and common age-related diseases.
- Second candidate SBT-272 shows promise for rare neurodegenerative diseases post preclinical data.
- None.
BOSTON, Oct. 30, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020, before the market opens.
Management will host a conference call at 8:30 am ET that day to discuss the financial results and provide a general business update. The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0921 (international) and referencing conference ID 13710878. A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/. A replay of the webcast will be archived on Stealth's website for 30 days following the event.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne and Becker muscular dystrophies and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, such as POLG-related disorders, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical stage candidate, SBT-272, for rare neurodegenerative disease indications following promising preclinical data in amyotrophic lateral sclerosis, or ALS. We have optimized our discovery platform to identify novel mitochondria-targeted compounds, including SBT-259, the SBT-550 series of compounds, and other compounds which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-report-third-quarter-2020-financial-results-on-thursday-november-5-2020-301164006.html
SOURCE Stealth BioTherapeutics Inc.
FAQ
When will Stealth BioTherapeutics report its third quarter 2020 financial results?
What time is the conference call for the financial results of Stealth BioTherapeutics?
How can I access the conference call for Stealth BioTherapeutics' Q3 results?
What is the focus of Stealth BioTherapeutics?
